eMIMS New Product
New drug - Volibris
29-Jul-08
GSK has launched Volibris (ambrisentan) for the treatment of pulmonary arterial hypertension (WHO Class II and III) to improve exercise capacity.
Ambrisentan is an endothelin receptor antagonist that blocks the endothelin A receptor on vascular smooth muscle cells and cardiac myocytes, preventing vasoconstriction and smooth muscle cell proliferation.
The recommended dose of Volibris is 5mg once daily. Some additional efficacy has been observed with 10mg once daily in patients with class III symptoms, however an increase in peripheral oedema has also been observed.
Patients with associated connective tissue disease may require 10mg once daily.
Volibris is currently the only drug licensed for patients with class II pulmonary arterial hypertension.
Further information: GSK 0800 221441
Quick search - use * for an abbreviated search, eg nico*
Tools
Related Articles
Related Drugs By Area
Latest Guidelines
- Osteoporotic Fragility Fractures in Postmenopausal Women: Primary Prevention (NICE)
- Osteoporotic Fragility Fractures in Postmenopausal Women: Secondary Prevention (NICE)
- VTE, Prevention of: Dabigatran (NICE)
- Influenza Prophylaxis: Oseltamivir, Amantadine and Zanamivir (NICE)
- Hepatitis B, Chronic: Entecavir (NICE)
Comments
Only registered users may comment. Log in now or register for a free account.